Clinical Trials Logo

Sarcoma clinical trials

View clinical trials related to Sarcoma.

Filter by:

NCT ID: NCT00073983 Completed - Sarcoma Clinical Trials

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Start date: October 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining gemcitabine with docetaxel may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with docetaxel in treating patients who have recurrent osteosarcoma, recurrent Ewing's sarcoma, or unresectable or locally recurrent chondrosarcoma.

NCT ID: NCT00070109 Completed - Clinical trials for Recurrent Childhood Rhabdomyosarcoma

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00069940 Completed - Sarcoma Clinical Trials

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

Start date: December 2000
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given together with sargramostim in treating patients with advanced sarcoma or brain tumor.

NCT ID: NCT00068367 Completed - Sarcoma Clinical Trials

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor

Start date: December 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with unresectable or metastatic malignant peripheral nerve sheath tumor.

NCT ID: NCT00066599 Completed - Lymphoma Clinical Trials

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Start date: June 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.

NCT ID: NCT00066365 Completed - Sarcoma Clinical Trials

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Start date: July 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the growth of tumor cells and shrink the tumor so that it can be removed during surgery. Sargramostim may then kill any tumor cells remaining after surgery. This may be an effective treatment for osteosarcoma that has spread to the lung. PURPOSE: This phase II trial is studying how well inhaled sargramostim works in treating patients who are undergoing surgery for the first recurrence of osteosarcoma that has spread to the lung.

NCT ID: NCT00064324 Completed - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

Start date: June 2003
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of perifosine in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00064220 Completed - Sarcoma Clinical Trials

Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who have advanced or metastatic soft tissue sarcoma.

NCT ID: NCT00064142 Completed - Clinical trials for AIDS-related Kaposi Sarcoma

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well halofuginone hydrobromide works in treating patients with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.

NCT ID: NCT00062283 Completed - Lung Cancer Clinical Trials

Alanosine in Treating Patients With Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well alanosine works in treating patients with soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.